Hard to say whether this will have a material change to revenues. Per the 2022 annual report, Hizentra sales were up 20% during 2022 and is the market leading product for subcutaneous immunoglobulin products.
Page 15 of the annual report shows that patients have a preference for Hizentra for at home dosing, so the pre-filled syringe is an obvious move to make.
Appears to not be all upside as this has lead to a decline in Privigen sales.
DYOR, IMO, blah blah
- Forums
- ASX - By Stock
- CSL
- News: CSL Csl Behring Receives FDA Approval For Hizentra® (Immune Globulin Subcutaneous <Origin...
CSL
csl limited
Add to My Watchlist
2.64%
!
$262.05

News: CSL Csl Behring Receives FDA Approval For Hizentra® (Immune Globulin Subcutaneous <Origin..., page-4
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$262.05 |
Change
6.740(2.64%) |
Mkt cap ! $127.0B |
Open | High | Low | Value | Volume |
$258.12 | $263.22 | $257.91 | $78.14M | 298.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 52 | $262.05 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$262.07 | 56 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 3 | 261.920 |
1 | 1 | 261.900 |
2 | 34 | 261.890 |
3 | 56 | 261.870 |
1 | 5 | 261.860 |
Price($) | Vol. | No. |
---|---|---|
261.960 | 40 | 4 |
261.970 | 47 | 6 |
261.980 | 6 | 1 |
261.990 | 34 | 3 |
262.000 | 4 | 1 |
Last trade - 11.18am 22/07/2025 (20 minute delay) ? |
Featured News
CSL (ASX) Chart |